)
US Commerce Secretary Howard Lutnick escalated criticism of India, urging New Delhi to lower tariffs and rethink Russian oil imports as trade tensions with Washington mount
High tariffs imposed by the United States on Indian goods pose a major risk to the country's growth, Crisil Intelligence said in its September report. The tariffs will impact both Indian goods exports and investments, the report added. However, domestic consumption, driven by benign inflation and rate cuts, is expected to support growth, it said. The country's GDP rose to a five-quarter high of 7.8 per cent in the first quarter of fiscal 2025-26, up from 7.4 per cent in the similar quarter in the previous year. Nominal GDP growth, however, slowed to 8.8 per cent from 10.8 per cent during the same period, it added. The report said consumer price index (CPI) inflation is likely to soften to 3.5 per cent in the current fiscal from 4.6 per cent in the previous year. Healthy agricultural growth is expected to keep food inflation under check, though the impact of excess rain was yet to be fully assessed. Lower crude prices and benign global commodity prices are expected to contain non
External Affairs Minister S Jaishankar has called on BRICS to defend the multilateral trading system amid increasing protectionism and tariff volatility during a meeting of the bloc's foreign ministers here on the sidelines of the UN General Assembly session. When multilateralism is under stress, BRICS has stood firm as a strong voice of reason and constructive change, Jaishankar said in a social media post. In a turbulent world, BRICS must reinforce the message of peacebuilding, dialogue, diplomacy and adherence to international law, he said. As rising protectionism, tariff volatility and non-tariff barriers impact trade flows, BRICS must defend the multilateral trading system, he said. Jaishankar's remarks come weeks after the US slapped 50 per cent tariffs on India, including an additional 25 per cent penalty for its purchase of Russian oil, among the highest in the world. The external affairs minister also called on the bloc to amplify its collective call for a comprehensive .
New Delhi seeks removal of penal tariffs on Russian oil purchases as Washington pushes soybean and corn sales, with both sides aiming to seal a trade pact by fall
Trump's 100% tariffs on branded drugs will spare Indian generics, though analysts see exposure for Sun Pharma, Biocon and Aurobindo, with Jubilant Pharmova set to benefit
Finance ministry warns tariff risks could hit jobs and consumption, while GST rationalisation and reforms are seen as key to sustaining India's growth amid global uncertainties
On Thursday, Trump announced another round of tariffs, which would go into effect on Oct 1, applying import duties ranging from 25 percent to 100 percent on pharmaceuticals, heavy trucks, etc
The index tracking domestic pharmaceutical stocks hit a low of 21,390 and then recouped some losses to end at 21,507
The EU is preparing 20 anti-dumping investigations against China to protect European industries from cheap imports and overcapacity in Chinese manufacturing
Sensex today | Stock Market crash highlights, Sept 26: In the broader markets, the Nifty MidCap index declined 2.05 per cent and the Nifty SmallCap index eased 2.2 per cent
Merck & Co., Novo Nordisk A/S and Eli Lilly & Co. are among firms that have started US builds since 2023, with construction sites in Delaware, North Carolina and Texas
Carysil stock, however, pared part of its losses after the company issued a clarification. Around 1:45 PM, the stock was trading 5.12 per cent lower at ₹806.40.
Among individual counters, Sun Pharma slumped 4.87 per cent to a fresh 52-week low of ₹1,548, while Gland Pharma tumbled 4.70 per cent to ₹1,880. Biocon declined 3.68 per cent to ₹342.85.
Shares of pharmaceutical companies across Asia tumbled in the aftermath, with Japan's Topix pharmaceutical index last down 1.2 per cent, while Hong Kong-listed innovative drug index fell 2 per cent
Indian pharma shares - Dr.Reddy's, Cipla, Sun, Lupin and Aurobindo Pharma stare at up to 30 downside risk hint technical charts as US President Donald Trump announces 100% tariff on pharma imports.
Trump said the new tariffs would not apply to companies that are actively building pharmaceutical manufacturing facilities in the US
Donald Trump hosted Pakistan PM Shehbaz Sharif at the White House, marking a thaw in US-Pakistan ties as India-US relations remain tense over tariffs and Russian oil imports
The Trump administration has launched trade probes on robotics, industrial machines, and medical devices, paving the way for possible tariffs to boost US manufacturing
The current tensions centre primarily on trade disputes, with the Trump administration imposing additional tariffs on India over various commercial issues
Wang said China and the US have reached a series of important consensus results after several rounds of economic and trade consultations